Home > Boards > US OTC > Biotechs > Vitro Diagnostics, Inc. (VODG)

VODG(.22)...next 4 months should be interesting......

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Potse Member Profile
 
Followed By 34
Posts 497
Boards Moderated 0
Alias Born 03/19/09
160x600 placeholder
Potse   Monday, 12/03/18 06:29:12 AM
Re: Potse post# 2266
Post # of 2302 
VODG(.22)...next 4 months should be interesting......

The next 4 months for VODG could turn out to be pretty interesting. Assuming the company maintains its schedule for financial performance press releases, we should be seeing at least two PRs in that time frame (FY 2018 and Q1 2019).

Given how informative its PRs have become, each of those press releases could be catalysts for tradeable spikes in the share price or sustained moves into higher trading ranges.

FY 2018 revenue should be well over $500k, and the quarter-over-quarter comparisons in early 2019 should look favorable. VODG has come a long way from the days when a $5-10K quarter was considered good.

I think it is a good idea to go back and read that Q3 press release again (see post above). VODG is telegraphing that business operations (on a number of fronts) are about to ramp up significantly in this coming year. That information regarding IRB-activity in foreign countries is potentially huge, especially when you consider how VODG's revenue to date has been positively influenced by exposure to basically just two clinics (New Zealand, Cayman Island).

https://vitrobiopharma.com/vitro-biopharma-3rd-quarter-ended-july-31st-2018-financial-results-of-operations/

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist